Electronic Supplementary Material

Drugs in R&D

Clinical and Preclinical Single-Dose Pharmacokinetics of VIR-2218, an RNAi Therapeutic Targeting HBV Infection

Sneha V. Gupta¹, Marie C. Fanget², Christopher MacLauchlin⁵, Valerie A. Clausen⁶, Jing Li⁶, Daniel Cloutier³, Ling Shen⁴, Gabriel J. Robbie⁷, Erik Mogalian¹

¹Clinical Pharmacology, ²Bioanalytical Sciences, ³Clinical Research, ⁴Biometrics, Vir Biotechnology, Inc., San Francisco, California, USA;
⁵Drug Metabolism and Pharmacokinetics, ⁶Bioanalytical Sciences, ⁷Clinical Pharmacology and Pharmacometrics, Alnylam Pharmaceuticals, Inc., Cambridge, Massachusetts, USA

E-mail address of the corresponding author: sgupta@vir.bio
Supplementary Information

**Table 1** Pharmacokinetic study design in rats and non-human primates (NHP)

|                  | Rat | NHP |
|------------------|-----|-----|
| Dose, mg/kg      | 10  | 10  |
| Number of doses  | 1   | 1   |
| Route            | SC  | SC  |
| Number of animals| 30  | 4   |

*SC* subcutaneous

**Table 2** Mean plasma pharmacokinetic parameters of VIR-2218 and AS(N-1)3’ VIR-2218 after a single SC dose (10 mg/kg) in rats and non-human primates (NHP)

|                  | Rat          | NHP          |
|------------------|--------------|--------------|
|                  | VIR-2218     | AS (N-1)3’VIR-2218 | VIR-2218 | AS (N-1)3’VIR-2218 |
| **T**<sub>max</sub> (h) | 1.0          | ND           | 2.6      | 2.8                |
| **C**<sub>max</sub>, µg/mL | 1.27         | ND           | 1.97     | 0.270              |
| **AUC<sub>last</sub>**, h*µg/mL | 2.83         | ND           | 12.3     | 1.55               |
| **t<sub>1/2</sub>***, h  | 6.7          | ND           | 2.9      | 5.1                |

*AU<sub>C</sub>last area under curve from time of dosing to last measurable time point, C<sub>max</sub> maximum concentration, t<sub>1/2</sub> half-life, ND not determined, T<sub>max</sub> time of C<sub>max</sub>*

*The reported t<sub>1/2</sub> values are not terminal.*